RDRachel Deplus

Rachel Deplus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rachel Deplus has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Emilie Calonne

    Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre (U-CRC), Université Libre De Bruxelles, Brussels, Belgium

    4 shared publications
  • Martin Bizet

    Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre (U-CRC), Université Libre De Bruxelles, Brussels, Belgium

    3 shared publications
  • Chao Li

    Max Born Crescent, Institute of Cell Biology, University of Edinburgh, Edinburgh, UK

    2 shared publications
  • François Fuks

    Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre (U-CRC), Université Libre de Bruxelles, 1070 Brussels, Belgium

    2 shared publications
  • François Fuks

    Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre, Université libre de Bruxelles (ULB), Institut Jules Bordet, Brussels, Belgium

    2 shared publications
  • Irina Stancheva

    Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann Building, Max Born Crescent, Edinburgh EH9 3BF, UK

    2 shared publications

Latest Publications

  • The chromatin remodelling protein LSH/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome

    by Maud De Dieuleveult, Martin Bizet, Laurence Colin, Emilie Calonne, Martin Bachman, Chao Li, Irina Stancheva, Benoit Miotto, François Fuks, Rachel Deplus

    Ten-Eleven Translocation (TET) proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) leading to a dynamic epigenetic state of DNA that can influence transcription and chromatin organization. While TET proteins interact with complexes involved in transcriptional repression and activation, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene expression still remains limited. Here, we show that TET proteins interact with the chromatin remodelling protein lymphoid-specific helicase (LSH/HELLS) in vivo and in vitro. In mouse embryonic fibroblasts (MEFs) and embryonic stem cells (ESCs) knock out of Lsh leads to a significant reduction of 5-hydroxymethylation amount in the DNA. Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with mild correlation with gene expression changes. We further show that differentially hydroxymethylated regions did not completely overlap with differentially methylated regions indicating that changes in 5hmC distribution upon Lsh knock-out are not a direct consequence of 5mC decrease. Altogether, our results suggest that LSH, which interacts with TET proteins, contributes to the regulation of 5hmC levels and distribution in MEFs and ESCs.


  • Open Access

    The chromatin remodeler LSH controls genome-wide cytosine hydroxymethylation

    by Maud de Dieuleveult, Martin Bizet, Laurence Colin, Emilie Calonne, Martin Bachman, Chao Li, Irina Stancheva, François Fuks, Rachel Deplus

    TET proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), leading to a dynamic epigenetic state of DNA that can influence transcription. While TET proteins have been associated with either epigenetic repression or activation complexes, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene transcription still remains limited. Here, we show that TET proteins interact with lymphoid-specific helicase (LSH), a chromatin remodeling factor belonging to the SNF2 super family. Lsh knock-out leads to a significant reduction of 5-hydroxymethylation global level in mouse embryonic fibroblasts (MEFs) and in embryonic stem cells (ESC). Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with not much effect on gene expression. We further show that 5hmC modifications upon Lsh loss is not a direct consequence of 5mC decrease, as differentially hydroxymethylated regions (DhMR) did not overlap with DMR (differentially methylated regions), underlying that these modifications occurred at different genomic loci. Altogether, our results suggest that LSH is a key regulator of 5hmC in both MEFs and ESC and that TET proteins rely on specific factors to establish genome-wide 5hmC patterns.


  • Open Access

    The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent

    by Carmen Brenner, Judith Luciani, Martin Bizet, Matladi Ndlovu, Eleonore Josseaux, Sarah Dedeurwaerder, Emilie Calonne, Pascale Putmans, Pierre- Francois Cartron, Matthieu Defrance, et al.

    The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent


  • MicroRNAs regulate KDM5 histone demethylases in breast cancer cells

    by Hélène Denis, Olivier Van Grembergen, Benjamin Delatte, Sarah Dedeurwaerder, Pascale Putmans, Emilie Calonne, Françoise Rothé, Christos Sotiriou, François Fuks, Rachel Deplus

    MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Alteration of miRNA levels is common in tumors and contributes to the pathogenesis of human malignancies. In the present study we examined the role played by miR-137 in breast tumorigenesis. We found miR-137 levels to be lower in breast cancer cells than in their non-tumorigenic counterparts and observed reduced proliferation and migration of breast cancer cells overexpressing miR-137. We further identified KDM5B, a histone demethylase known to be involved in breast cancer tumorigenesis, as a target of miR-137. As the involvement of histone demethylases in cancer is still poorly understood and as the role of miRNAs in controlling epigenetic mechanisms in cancer is emerging, we broadened our study to the whole KDM5 histone demethylase family to see if the genes coding for these epigenetic enzymes might be regulated by miRNAs in cancer cells. We discovered that KDM5C is overexpressed in breast cancer cells, providing evidence that miR-138 regulates its expression. We found miR-138 overexpression to affect breast cancer cell proliferation. Altogether, our findings suggest that miRNAs may regulate KDM5 histone demethylase levels in breast cancer and thereby control breast cancer cell proliferation and migration.